リサンキズマブで治療されたクローン病患者の長期的結果
Grace Geeganage1, Ajay Gade1, Alessandra Saraga1
1Division of Gastroenterology, Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.
Inflammatory bowel diseases
|August 26, 2025
まとめ
リサンキズマブは,クローン病 (CD) の治療において実用的な有効性を示しています. 浸透性CDは治療の失敗を予測し,近経性フィストル化CDと以前の生物学的使用はエスカレーションを予測する.
科学分野:
- 胃腸内科
- 免疫学
- 薬理学について
背景:
- クローン病 (Crohn' s disease) のリサンキズマブに関する既存のデータは,主に制限されたフォローアップによる制御試験に由来する.
- 現実世界の有効性と安全性のデータは,多様な患者集団における長期的な結果を理解するために不可欠です.
- この研究は,CD管理におけるリサンキズマブの長期的な実用的な証拠の必要性に対処しています.
研究 の 目的:
- クローン病患者の実際のコホートにおけるリサンキズマブの長期的な有効性と安全性を評価する.
- リサンキズマブを投与された患者の治療失敗とエスカレーションに関連する要因を特定する.
- リサンキズマブ治療中のCD関連の医療利用を評価する.
主な方法:
- リサンキズマブで治療されたCD患者106人を対象とした単一センターコホート研究.
- 治療失敗,エスカレーション,医療利用の時間分析
- 治療開始から中止までのフォローアップまたは2024年10月
主要な成果:
- 13% の患者は治療に失敗し,23% は治療のエスカレーションが必要でした.
- 患者の16%はCD関連の医療利用でした.
- 浸透性CD (HR 5. 2) は治療失敗と関連しており,近経性フィストル化CD (HR 3. 3) と2種以上の生物学的薬 (HR 5. 8) に先行した曝露はエスカレーションと関連していた.
結論:
- リサンキズマブは,この現実の長期CDコホートにおいて,一般的な有効性を示した.
- 特定の疾患のフェノタイプ (浸透性,近経フィストル性CD) と以前の治療歴は治療結果に影響します.
- これらの発見は,CDにおけるリサンキズマブの反応を予測する患者特有の要因の重要性を強調しています.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Inflammatory Bowel Disease II: Crohn's Disease
382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419


